|
|||||||||||||||||||||
|
 研究者DBへ |
||||||||||||||||||||
| 注意：各教員のメールアドレスは“@”マークを“★”にかえてあります | |||||||||||||||||||||
メッセージ |
| 癌化学療法の個別化が発展するには、治療薬の効果予測に有用なバイオマーカーの解明と高精度の検査技術が欠かせません。近年、内分泌療法薬や分子標的治療薬の適応判定技術が普及し、投与の個別化が進んできました。一方で、従来の抗癌剤は内分泌療法薬や分子標的治療薬よりもはるかに多くの患者さんに投与されるにも関わらず、その適応判定法はいまだ未開発の状態です。従来の抗癌剤の個別化投与が実現すれば、副作用に苦しめられる患者さんは劇的に少なくなるに違いありません。当研究室では、全国屈指の免疫染色技術を生かし、抗癌剤の感受性を予測する研究（病理学・免疫組織化学を基盤とした臨床研究）を続けています。病理学に対する熱意を持ち、真剣に取り組む学部学生、大学院生の参加を歓迎します。 |
研究テーマ |
|
|
社会活動 |
| 日本病理学会学術評議員、Pathology International刊行委員、日本組織細胞化学会評議員、Acta Histochemica et Cytochemica編集委員 |
最近の主な著書 |
| ・松原修、鴨志田伸吾ほか（著）「最新臨床検査学講座 病理学／病理検査学」、医歯薬出版（共著） ・沢辺元司、長坂徹郎（編）「スタンダード病理学、第4版」、文光堂（共著） ・鴨志田伸吾（著）「免疫染色 至適条件決定法」、学際企画 ・名倉 宏、長村義之、堤 寛（編）「渡辺・中根 酵素抗体法、改訂4版」、学際企画（共著） |
最近の論文 |
Ogane N, et al.: Cleaved caspase-3 expression is a potential prognostic factor for endometrial cancer with positive peritoneal cytology. Cytopathology 29: 254-261, 2018 Konishi M, et al.: Correlation of expression levels of copper transporter 1 and thymidylate synthase with treatment outcomes in patients with advanced non-small cell lung cancer treated with S-1/carboplatin doublet chemotherapy. Asian Pac J Cancer Prev 19: 435-441, 2018 Mashud R, et al.: Impaired lymphocyte trafficking in mice deficient in the kinase activity of PKN1. Sci Rep 7: 7663, 2017 Kimura M, et al.: Protein and mRNA expression of folic acid-associated enzymes as biomarkers for the cytotoxicity of the thymidylate synthase-targeted drugs, pemetrexed and S-1, in non-small cell lung cancer. Mol Clin Oncol 7: 15-23, 2017 Kawamura J, et al.: Filter paper-assisted cell transfer (FaCT) technique: a novel cell sampling technique for intraoperative diagnosis of central nervous system tumors. Cancer Cytopathol 125: 277-282, 2017 Naito Y, et al.: Anti-hyperglycemic effect of long-term bis(hinokitiolato)zinc complex ([Zn(hkt)2]) ingestion on insulin resistance and pancreatic islet cells protection in type 2 diabetic KK-Ay mice. Biol Pharm Bull 40: 318-326, 2017 Shintani M, et al.: Expression of chromosomal regional maintenance protein-1 may be associated with subcellular survivin expression in human gastric and colorectal carcinoma. Oncol Lett 12: 4630-4634, 2016 Shimakata T, et al.: Immunohistochemical expression profiles of solute carrier transporters in α-fetoprotein-producing gastric cancer. Histopathology 69: 812-821, 2016 Hamamoto Y, et al.: Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression. Rare Diseases 4: e1165909, 2016 Ohta S, et al.: Evaluation of thymidylate synthetase expression in prostate cancer. Current Urol 8: 194-198, 2015 Takeda R, et al.: Impact of expression levels of platinum-uptake transporters, copper transporter 1 and organic cation transporter 2, on resistance to anthracycline/taxane-based chemotherapy in triple-negative breast cancer. Breast Cancer (Auckl) 9: 49-57, 2015 Naka A, et al.: Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer. Am J Cancer Res 5: 2285-2293, 2015 Shintani M, et al.: Smac/DIABLO expression in human gastrointestinal carcinoma: association with clinicopathological parameters and survivin expression. Oncol Lett 8: 2581-2586, 2014 Tashiro A, et al.: High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy. Am J Cancer Res 4: 528-536, 2014 Sangawa A, et al.: Phosphorylation status of Akt and caspase-9 in gastric and colorectal carcinomas. Int J Clin Exp Pathol 7: 3312-3317, 2014 Hashimoto Y, et al.: Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Res Treat 145: 101-111, 2014 Tatsumi S, et al.: Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. Int J Clin Exp Pathol 7: 204-212, 2014 |